BioCryst Pharmaceuticals (BCRX) : The short interest in BioCryst Pharmaceuticals (BCRX) has changed with an increase of 1,608,244 shares and the open interest is 30.4%. From 5,285,591 short positions on Jul 29, 2016, the shorts increased to 6,893,835 shares by August 15, 2016. There are 3 more days left for the expiry and the daily trading volume of the stock is 2,146,399 shares. The total interest of shorts is 10% of the shares available to the public. The short interest information was released on Wednesday Aug 24th after the market close.
BioCryst Pharmaceuticals (NASDAQ:BCRX): The stock opened at $4.65 on Wednesday but the bulls could not build on the opening and the stock topped out at $4.84 for the day. The stock traded down to $4.34 during the day, due to lack of any buying support eventually closed down at $4.39 with a loss of -5.39% for the day. The stock had closed at $4.64 on the previous day. The total traded volume was 1,177,798 shares.
In a related news, Staab Thomas R Ii, officer (Senior Vice President and CFO) of Biocryst Pharmaceuticals Inc, unloaded 5,864 shares at an average price of $5.14 on August 11, 2016. The total amount of the transaction was worth $30,141, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.